Pembrolizumab in PD-L1-positive advanced non-small cell lung carcinoma: A meta-analysis of survival benefits and immune-related toxicity events patterns: Original scientific article. (2025). ADMET and DMPK, 13(5), 2956. https://doi.org/10.5599/admet.2956